IP Library Granted Patent US 7,781,488
Granted Patent B2
US 7,781,488 · App. 10/516,118 · Granted Aug 24, 2010

Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,781,488
App. No.
10/516,118
Granted
Aug 24, 2010
Kind
B2
Abstract

The present invention provides a method and compositions for synthesizing an oligopeptide or polypeptide by convergent assembly of a plurality of pairs of oligopeptides in chemical ligation reactions. An important aspect of the present invention is an oligopeptide having a C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester moiety. This allows a single precursor to participate in a succession of chemical ligation reactions, thereby making the convergent synthesis approach possible. The present invention is useful in methods for chemical synthesis of oligopeptides, polypeptides and proteins, and improves the efficiency of native chemical ligation reactions, particularly where four or more peptide fragments are used to assemble an oligopeptide, polypeptide or protein product.

Claims (32)

1. A method for preparing an oligopeptide or polypeptide product, comprising:

(a) ligating in a first reaction, first and second oligopeptides each having an N-terminus and a C-terminus, wherein said first oligopeptide comprises a C-terminus having a thioester group, and an N-terminus that is substantially unreactive with said thioester group, wherein said second oligopeptide comprises an N-terminus having an unprotected cysteine, an unprotected 1,2-amino thiol, or an unprotected 1,3-amino thiol, and a C-terminus having an inactive thioester precursor, and wherein said ligating forms a first oligopeptide ligation product comprising a C-terminus having an inactive thioester precursor, and an N-terminus that is substantially unreactive with said thioester group;

(b) ligating in a second reaction, third and fourth oligopeptides each having an N-terminus and a C-terminus, wherein said third oligopeptide comprises an N-terminus having a protected cysteine, a protected 1,2-amino thiol, or a protected 1,3-amino thiol, and a C-terminus comprising a thioester, wherein said fourth oligopeptide comprises an N-terminus having an unprotected cysteine, an unprotected 1,2-amino thiol, or an unprotected 1,3-amino thiol, and a C-terminus that is substantially unreactive with said unprotected cysteine, said unprotected 1,2-amino thiol, or said unprotected 1,3-amino thiol, and wherein said ligating forms a second oligopeptide ligation product comprising an N-terminus having a protected cysteine, a protected 1,2-amino thiol, or a protected 1,3-amino thiol, and a C-terminus that is substantially unreactive with said unprotected cysteine, said unprotected 1,2-amino thiol, or said unprotected 1,3-amino thiol;

(c) transforming said inactive thioester precursor of said first oligopeptide ligation product of step (a) into a thioester to form a third oligopeptide ligation product having a C-terminus comprising a thioester, and an N-terminus that is substantially unreactive with said thioester group;

(d) deprotecting said N-terminus of said second oligopeptide ligation product of step (b) to form a fourth ligation product comprising an N-terminus having an unprotected cysteine, an unprotected 1,2-amino thiol, or an unprotected 1,3-amino thiol, and a C-terminus that is substantially unreactive with said unprotected cysteine, said unprotected 1,2-amino thiol, or said unprotected 1,3-amino thiol; and

(e) ligating said third oligopeptide ligation product of step (c) to said fourth oligopeptide ligation product of step (d) to form a fifth oligopeptide ligation product comprising an N-terminus that is substantially unreactive with an oligopeptide bearing a C-terminal thioester group, and a C-terminus that is substantially unreactive with an oligopeptide bearing an unprotected N-terminal cysteine, an unprotected 1,2-amino thiol, or an unprotected 1,3-amino thiol,

wherein:

said inactive thioester precursor at said C-terminus is defined by the formula:

Xaa i - . . . -Xaa m -(CH—R)—CO—O—CH[(CH 2 ) n —S—R′]—Y

wherein:

Xaa i is a protected or unprotected amino acid for i=1 to m;

m is an integer from 2 to 200;

n is an integer from 1 to 10;

R is an amino acid side chain;

R′ is a member selected from the group consisting of a sulfur protecting group and —SR″;

R″ is a member selected from the group consisting of C 2-10 alkyl, substituted aryl having from 5 to 12 carbon atoms, substituted benzyl, and substituted heteroaryl having from 5 to 12 carbon atoms and 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;

Y is an electron withdrawing group selected from the group consisting of R c , C 1-3 alkyl substituted with 1-3 R c groups, —C(O)—R d , —S(O)p-C 1-3 alkyl substituted with 0-3 R c groups, and an aryl substituted with 1-3 R c groups;

each R c group is independently a member selected from the group consisting of halogen, polyhaloalkyl, substituted or unsubstituted benzyl, substituted or unsubstituted aryl, —C(O)NH 2 , —C(O)—NHNH 2 , —S(O) 2 NH 2 , substituted and unsubstituted hydroxyl-amine, cyano, nitro and quaternary ammonium salts;

p is an integer from 1 to 2;

R d is a member selected from the group consisting of hydrogen, N(R e ) 2 , —OR e and —SR e ;

each R e is independently a member selected from the group consisting of hydrogen, C 1-3 alkyl substituted with 0-3 R c groups, and —SO 2 —C 1-3 alkyl substituted with 1-3 R c groups; alternatively,

when two R e groups are present, they can be taken together with the atom to which they are attached to form a 5-6 membered non-aromatic heterocylic ring containing 1-3 heteroatoms each independently selected from the group consisting of N, O and S, substituted with 0-3 R c groups.

2. The method of claim 1 further comprising: (f) ligating said fifth oligopeptide ligation product of step (e) to one or more additional oligopeptides, with the proviso that said fifth oligopeptide ligation product of step (e) and said one or more additional oligopeptides bear, or are prepared to bear N-terminal and C-terminal groups capable of chemical ligation, wherein said N-terminal group capable of chemical ligation comprises an unprotected cysteine, an unprotected 1,2-amino thiol, or an unprotected 1,3-amino thiol, and wherein said C-terminal group capable of chemical ligation comprises a thioester.

3. The method of claim 2 wherein Y is —C(O)NH 2 .

4. The method of claim 1 wherein said N-terminus of said fifth oligopeptide ligation product of step (e) comprises an unprotected N-terminal amino acid, or a protected N-terminal amino acid.

5. The method of claim 4 wherein said protected N-terminal amino acid is cyclic.

6. The method of claim 4 wherein said protected N-terminal amino acid comprises a protected cysteine, a protected 1,2-amino thiol, or a protected 1,3-amino thiol.

7. The method of claim 1 wherein said C-terminus of said fifth oligopeptide ligation product of step (e) comprises an unprotected amino acid, or an inactive thioester precursor.

8. The method of claim 1 wherein R′ is a sulfur protecting group.

9. The method of claim 1 wherein R′ is —SR″.

10. The method of claim 1 wherein R″ is a member selected from the group consisting of ethyl, t-butyl and substituted phenyl.

11. The method of claim 1 wherein each step is performed in a solution selected from the group consisting of an organic solvent and an organic and aqueous solvent mixture.

Assignments (5)
AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP Recorded Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →
CHANGE OF NAME Recorded Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2007
From: GENEPROT, INC.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 018916/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2007
From: GENEPROT, INC.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 018916/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2006
From: BOTTI, PAOLO; VILLAIN, MATTEO; MANGANIELLO, SONIA; GAERTNER, HUBERT
To: GENEPROT, INC.
Reel/Frame 018445/0493 →